SU 6656;1H-Indole-5-sulfonamide, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-;SU 6656 (SU-6656, SU6656);SU-6656;2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide;SU6656
Cas No.
330161-87-0
分子式
C19H21N3O3S
分子量
371.45
包装储存
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
生物活性
SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
性状
Solid
体外研究(In Vitro)
SU6656 decreases phosphorylation of Src family kinases (SFKs) in HNSCC cells.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
SU6656 (2-4 mg/kg; i.p.; once) significantly decreases ischemic postconditioning (IPoCo) mediated increase in fall down time.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Swiss albino male mice
Dosage:
2, 4 mg/kg
Administration:
Intraperitoneal injection; once
Result:
Significantly decreased IPoCo mediated increase in fall down time.